Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2022-05-09 Interim / Quarterly Rep…
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2022
2022-05-09 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2022, reporting business updates and financial results for the fiscal quarter ended March 31, 2022. It includes a press release as an exhibit announcing quarterly financial results. The document is relatively short (3896 characters) and primarily serves as a current report to announce quarterly earnings results, not a full detailed financial report. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Therefore, the appropriate classification is ER.
2022-05-09 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes voting items such as election of directors, ratification of auditors, executive compensation approval, and amendment of the certificate of incorporation. The text explicitly mentions it is proxy material for the Annual Meeting and provides instructions for voting. This type of document corresponds to Proxy Solicitation & Information Statement filings, which provide information to shareholders to solicit votes for meetings. The document length is under 5,000 characters and it is not a full report but proxy materials. Therefore, the correct classification is PSI (Proxy Solicitation & Information Statement).
2022-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-29 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-04-28 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC for the 2022 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. It includes detailed information about the meeting agenda, proposals to be voted on, board of directors, executive compensation, and other governance matters. The document is not an annual report, earnings release, or financial statement, but rather a solicitation of proxies and information for shareholders to vote at the annual meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), and it contains the full proxy statement, not just an announcement or notice. Therefore, the correct classification is PSI with high confidence.
2022-04-18 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.